Protagonist Therapeutics, Inc. (PTGX) Financial Analysis & Valuation | Quarter Chart
Protagonist Therapeutics, Inc. (PTGX)
PTGXPrice: $121.63
Fair Value: 🔒
🔒score
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II cli... more
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based th... more
Description
Shares
| Market Cap | $7.82B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Dinesh V. Patel |
| IPO Date | 2016-08-11 | CAGR | — |
| Employees | 124 | Website | www.protagonist-inc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PTGX chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.04B | P/E Ratio | -67.2 |
| Forward P/E | -177.65 | PEG Ratio | — |
| P/S Ratio | 632.52 | P/B Ratio | 72.19 |
| P/CF Ratio | -406.43 | P/FCF Ratio | -402.68 |
| EPS | $-1.81 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -64.36% | Gross Margin | 0.99% |
| Operating Margin | -1.92% | Profit Margin | -1.55% |
| ROE | -0.18% | ROA | -0.16% |
| ROCE | -0.21% | Current Ratio | 17.76 |
| Quick Ratio | 17.76 | Cash Ratio | 5.61 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 111.21 | Piotroski Score | 1 |